DOI: 10.3390/life13091835 ISSN:

Advances in the Cystic Fibrosis Drug Development Pipeline

Christine Esposito, Martin Kamper, Jessica Trentacoste, Susan Galvin, Halie Pfister, Janice Wang
  • Paleontology
  • Space and Planetary Science
  • General Biochemistry, Genetics and Molecular Biology
  • Ecology, Evolution, Behavior and Systematics

Cystic fibrosis is a genetic disease that results in progressive multi-organ manifestations with predominance in the respiratory and gastrointestinal systems. The significant morbidity and mortality seen in the CF population has been the driving force urging the CF research community to further advance treatments to slow disease progression and, in turn, prolong life expectancy. Enormous strides in medical advancements have translated to improvement in quality of life, symptom burden, and survival; however, there is still no cure. This review discusses the most current mainstay treatments and anticipated therapeutics in the CF drug development pipeline within the mechanisms of mucociliary clearance, anti-inflammatory and anti-infective therapies, restoration of the cystic fibrosis transmembrane conductance regulator (CFTR) protein (also known as highly effective modulator therapy (HEMT)), and genetic therapies. Ribonucleic acid (RNA) therapy, gene transfer, and gene editing are being explored in the hopes of developing a treatment and potential cure for people with CF, particularly for those not responsive to HEMT.

More from our Archive